Lexeo Therapeutics, Inc. Common Stock
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LXEO research report →
Companywww.lexeotx.com
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations.
- CEO
- R. Nolan Townsend
- IPO
- 2023
- Employees
- 75
- HQ
- New York City, US
Price Chart
Valuation
- Market Cap
- $374.55M
- P/E
- -4.43
- P/S
- 0.00
- P/B
- 1.67
- EV/EBITDA
- -3.55
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -47.48%
- ROIC
- -40.94%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-99,961,000 · -1.66%
- EPS
- $-1.86 · 39.81%
- Op Income
- $-109,257,000
- FCF YoY
- -21.22%
Performance & Tape
- 52W High
- $10.99
- 52W Low
- $2.51
- 50D MA
- $5.97
- 200D MA
- $7.15
- Beta
- 1.53
- Avg Volume
- 887.75K
Get TickerSpark's AI analysis on LXEO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 28, 26 | Sepp-Lorenzino Laura | other | 50,000 |
| Apr 28, 26 | Sepp-Lorenzino Laura | other | 0 |
| Apr 6, 26 | Townsend Richard Nolan | sell | 55,000 |
| Mar 13, 26 | Townsend Richard Nolan | other | 2,623 |
| Mar 13, 26 | Otero Jose Manuel | other | 5,930 |
| Feb 18, 26 | Otero Jose Manuel | sell | 3,016 |
| Feb 18, 26 | Townsend Richard Nolan | sell | 10,173 |
| Nov 18, 25 | Otero Jose Manuel | sell | 721 |
| Feb 13, 26 | Bhalla Narinder Pal | other | 297,000 |
| Feb 13, 26 | Bhalla Narinder Pal | other | 49,500 |
Our LXEO Coverage
We haven't published any research on LXEO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LXEO Report →